CSI Market
Sign In | Register

Generex Biotechnology (GNBT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access GNBT quarterly Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Generex Biotechnology's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Jul 31 2020)
12 Months 		(Jul 31 2019) (Jul 31 2018) (Jul 31 2017) (Jul 31 2016)
Operating Activities
Income-34.23
Depreciation & amortization0.83
Amortization of Other Assets4.59
Increase (Decrease) in Deferred Revenue0.00
Other Asset Impairment Charges0.94
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.11
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.19
Share-based Compensation2.40
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Reduction Of Notes Receivable Common Stock Exchange For Services Rendered-
Write Off Of Uncollectible Notes Receivable Common Stock-
Write Off Of Deferred Debt Issuance Cost-
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost-
Amortization Of Options And Option Modifications As Employee Compensation-
Common Stock Issued For Services Rendered-
Amortization Of Prepaid Services In Conjunction With Common Stock Issuance-
Issuance Of Warrants Additional Exercise Right Inducement-
Preferred Stock Issued For Services Rendered-
Treasury Stock Redeemed For Non Performance Of Services-
Amortization Of Deferred Debt Issuance Costs Loan Origination Fees-
Founders Shares Transferred For Services Rendered-
Fees In Connection With Refinancing Of Debt-
Stock Issued During Period Value Issued For Services-
Common Stock Issued For Makewhole Payments On Preferred Stock-
Goodwill And Intangible Asset Impairment4.41
Noncash Interest Expense From Issuance On Debt Derivative-
Change In Fair Value Of Derivative Liabilities Convertible Notes-0.31
Change In Fair Value Of Common Stock Payable-0.88
Increase Decrease In Contract With Customer Liability0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.01
Accounts Payable10.04
Increase (Decrease) in Interest Payable, Net0.86
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Intangible Assets, Current0.00
Other Working Capital-0.15
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities5.32
Discontinued operations0.00
Net Cash flow from Operating Activities-6.12
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Received In Acquisition Of Business0.05
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.04
Financing Activities
Short-term debt Net6.63
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.94
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.11
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.01
Change In Notes Receivable Common Stock-
Payment Of Costs Associated With Convertible Debentures-
Proceeds From Convertible Note Payable-
Repayment Of Convertible Note Payable-
Investment In Subsidiary By Noncontrolling Interest-
Antigen Dividen-
Conversion Of Hds Debt And Issuance Of Call Option-
Conversion Of Debts To Equity-
Exercise Of Call Option-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.81
Effect of exchange rate on cash flow-0.02
Discontinued operations0.00
Free Cash Flow-6.13
Total Cash Flow-0.28
4 historic quarters locked

Sign in to unlock the full Generex Biotechnology cash flow history.

Sign In Create Free Account

About GNBT Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License